Trevi's Haduvio reduces chronic cough by 57% vs placebo in Phase 2a trial, surpassing expectations. Stock rises 40%.

Arrowhead Pharmaceuticals on Monday shared new open-label data in about a dozen patients for a program designed to improve ...